What is the role of immune modulators in the treatment of mastocytosis?

Updated: Sep 16, 2020
  • Author: Jacquiline Habashy, DO, MSc; Chief Editor: Dirk M Elston, MD  more...
  • Print

Future novel therapy for cutaneous mastocytosis includes immune modulators. One successful case report from 2008 described treatment of progressive c-kit mutation cutaneous mastocytosis with imatinib, halting disease symptoms and progression and improving the length of disease course. [48] Imatinib is approved by the Food and Drug Administration for use in patients with aggressive systemic mastocytosis with organ dysfunction due to progressive infiltration of various organs by mast cells without D816V c-kit mutation or unknown c-kit mutation status. [49]

Masitinib may be superior to sunitinib as second-line therapy for patients who are imatinib resistant with systemic or severe cutaneous mastocytosis. [50]

Improvements in wheal formation and systemic symptoms may be seen with omalizumab, anti-immunoglobulin E therapy, in a patient with cutaneous mastocytosis and Ménière disease. [51, 52, 53, 54]

Pimecrolimus and other calcineurin inhibitors may be another potential therapy for mastocytosis and other mast cell-associated diseases. [55, 56]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!